What to Know About Mucolytics

Drugs Designed to Break Up and Loosen Mucus

Table of Contents
View All
Table of Contents

Mucolytics are a class of drugs used to help break up and thin mucus, making it easier to clear from the airways. They are used to treat respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other conditions including common colds marked by excess mucus and a productive cough.

Types of mucoactive agents include expectorants, mucolytics, mucoregulators, and mucokinetics, and they are often taken orally or breathed in via a nebulizer. Mucolytics work best if taken consistently.

A pill capsule on a white background
Markus Gann / EyeEm / Getty Images


Overproduction of mucus in the lungs—usually seen with COPD or sometimes with a lower respiratory infection—is caused by inflammation that results in an increase in both the number and size of so-called goblet cells that line the air passages.

While goblet cells normally secrete mucus as a form of protection, with COPD, for example, the excessive production can clog the passages, making it harder to breathe.

One way of clearing this buildup is with an oral or nebulized drug called a mucolytic. Mucolytics work by dissolving the chemical bonds within the secretions, breaking them so they can be more readily coughed up.

Your healthcare provider may prescribe or recommend that you use a mucolytic if thick mucus is a substantial contributor to your symptoms. Generally, you would take only one mucolytic, and they are usually used short-term, but some people need to take a mucolytic repeatedly if the condition recurs.

Off-Label Uses

While mucolytics are not considered part of the current standard of care for COPD treatment, the 2017 guidelines issued by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggest that the drugs may be useful in people who can't take inhaled corticosteroids. They may also be helpful for those who have difficulty with handheld inhalers.

Given the concerns about the safety of long-term corticosteroid use, there have been suggestions that mucolytics may be appropriate in advanced COPD, where the risk of exacerbation is high irrespective of steroid use. In these cases, mucolytics may help reduce the number of exacerbations and offer some improvement in the quality of life.

Before Taking

Mucolytics can be taken orally in a tablet or syrup formulation, or inhaled through a nebulizer. Some of the more common types of mucolytics include:

  • Mucinex (guaifenesin)
  • Carbocisteine
  • Pulmozyme (dornase alfa)
  • Erdosteine
  • Mecysteine
  • Bromhexine
  • Hyperosmolar saline
  • Mannitol powder

The various types of mucolytic agents each have a different action:

  • Expectorants increase airway water to help with mucus clearing.
  • Mucoregulators increase the movement of mucus via cough.
  • Mucokinetics suppress the mechanisms causing excess mucus secretions.

Carbocisteine, for example, is a mucolytic that acts on the metabolism of the goblet cells and also offers antioxidant and anti-inflammatory benefits. Guaifenesin, by contrast, increases the water content of the mucus, thinning it out so that it can be coughed up.

Your healthcare provider would determine which mucolytic you take based on your symptoms and the other medication you take.

Precautions and Contraindications

Most mucolytics are very safe, but should not be used in children under 6. Do not take mucolytics if you have a stomach ulcer.

Consult your healthcare provider or pharmacist before taking mucolytics if you are pregnant or breastfeeding.


Dosage of mucolytics depends on the type of drug you're taking and the condition you're taking it for, in addition to whether you're taking a pill, liquid, or using a nebulizer. As some mucolytics don't stay in the system very long, you may need to take them consistently for a period of time.

Talk to your healthcare provider about the proper dosage, delivery method, and duration for your condition.

Side Effects

The side effects can also vary both by drug type and formulation. Broadly speaking, nausea and diarrhea are the most common side effects associated with tablets, while liquids may also cause bronchial spasms and rashes.

Nebulized formulations can similarly cause a sore throat, runny nose, and the formation of white patches in the mouth or lips.

By and large, mucolytics are considered safe and associated with a low risk of adverse events. With that being said, it's always important to speak with your healthcare provider about any side effects, interactions, or contraindications associated with a mucolytic product, whether prescribed or purchased over-the-counter. 

Was this page helpful?
7 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Aaron SD. Mucolytics for COPD: negotiating a slippery slope towards proof of efficacy. Eur Respir J. 2017;50(4) doi:10.1183/13993003.01465-2017

  2. Singanayagam A, Glanville N, Girkin JL, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbationsNat Commun. 2018;9(1):2229. doi:10.1038/s41467-018-04574-1

  3. Global Initiative for Chronic Obstructive Lung Disease. Pocket guide to COPD diagnosis, management, and prevention: a guide for health care professionals (2017 report). 2017

  4. Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD. Respirology. 2016;21(7):1152-65. doi:10.1111/resp.12780

  5. Zeng Z, Yang D, Huang X, Xiao Z. Effect of carbocisteine on patients with COPD: a systematic review and meta-analysisInt J Chron Obstruct Pulmon Dis. 2017;12:2277–2283. doi:10.2147/COPD.S140603

  6. Albrecht HH, Dicpinigaitis PV, Guenin EP. Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infectionsMultidiscip Respir Med. 2017;12:31. doi:10.1186/s40248-017-0113-4

  7. Yoon H, Lee DH. Mucolytics as adjuvant agent to improve helicobacter pylori eradication rate: still long and winding road to positive resultsGut Liver. 2015;9(3):257–258. doi:10.5009/gnl15117

Additional Reading